Leap Price To Book Ratio from 2010 to 2024

LPTX Stock  USD 2.95  0.18  5.75%   
Leap Therapeutics Price To Book Ratio yearly trend continues to be fairly stable with very little volatility. Price To Book Ratio is likely to outpace its year average in 2024. Price To Book Ratio is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. View All Fundamentals
 
Price To Book Ratio  
First Reported
2010-12-31
Previous Quarter
1.40740512
Current Value
1.41
Quarterly Volatility
4.77929064
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Leap Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Leap Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 336.9 K, Interest Expense of 4.8 K or Selling General Administrative of 8.7 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0025 or PTB Ratio of 1.41. Leap financial statements analysis is a perfect complement when working with Leap Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Leap Therapeutics Correlation against competitors.
For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Latest Leap Therapeutics' Price To Book Ratio Growth Pattern

Below is the plot of the Price To Book Ratio of Leap Therapeutics over the last few years. It is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. Leap Therapeutics' Price To Book Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Leap Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price To Book Ratio10 Years Trend
Slightly volatile
   Price To Book Ratio   
       Timeline  

Leap Price To Book Ratio Regression Statistics

Arithmetic Mean1.71
Geometric Mean2.83
Coefficient Of Variation279.18
Mean Deviation2.68
Median2.86
Standard Deviation4.78
Sample Variance22.84
Range19.6037
R-Value(0.31)
Mean Square Error22.25
R-Squared0.1
Significance0.26
Slope(0.33)
Total Sum of Squares319.78

Leap Price To Book Ratio History

2023 1.41
2022 0.87
2021 2.58
2020 2.86
2019 -14.46
2018 3.08
2017 5.14

About Leap Therapeutics Financial Statements

Leap Therapeutics investors use historical fundamental indicators, such as Leap Therapeutics' Price To Book Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Leap Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Book Ratio 1.41  1.41 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.